You are here: Industry Insights > AstraZeneca

News List

Akoya and AstraZeneca Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology americanpharmaceuticalreview
June 09, 2021
Akoya Biosciences Inc. and The Spatial Biology Company® announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures, based on Akoya’s Phenoptics™ platform.
Imfinzi Demonstrates Unprecedented Survival in Lung Cancer americanpharmaceuticalreview
June 08, 2021
The PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable ...
AstraZeneca Appoints Aradhana Sarin As New Chief Financial Officer americanpharmaceuticalreview
June 08, 2021
AstraZeneca PLC announced that the Board has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals, Inc. (Closing) and effective on the later of ...
AZ delivers 1.8m doses ahead of mass rollout firstwordpharma
June 07, 2021
Thailand's publish health ministry said AstraZeneca delivered 1.8 million locally produced COVID-19 vaccine doses, the first of 6 million scheduled for delivery this month, reported the Bangkok Post.
Lynparza shows promise in preventing cancer recurrence pharmatimes
June 04, 2021
AstraZeneca and MSD's Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Long-Haul COVID Symptoms? Getting Vaccine Won't Make You Feel Worse, Study Finds drugs
June 02, 2021
COVID survivors can relax when it comes to vaccination: A new study shows that getting immunized will not worsen any symptoms that linger long after infection, such as breathing difficulties, fatigue and insomnia.
EU clears Tagrisso for early-stage EGFR-mutated lung cancer pharmatimes
June 01, 2021
The European Commission (EC) has approved AstraZeneca’s (AZ) Tagrisso for the adjuvant treatment of early-stage, epidermal growth factor receptor mutated (EGFR) non-small cell lung cancer (NSCLC) following surgery.
Competition and Markets Authority investigating AstraZeneca’s Alexion acquisition europeanpharmaceuticalreview
May 31, 2021
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
Astrazeneca gives rights to trademark for three diabetes drug brands to Sun Pharma expresspharma
May 31, 2021
Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for the distribution of Dapagliflozin.
Possible Cause Found for Rare Blood Clots Tied to Some COVID-19 Vaccines drugs
May 31, 2021
The cause of rare blood clots in some people who have received the AstraZeneca and Johnson & Johnson COVID-19 vaccines has been found, researchers report.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page